1. Home
  2. STEC vs INKT Comparison

STEC vs INKT Comparison

Compare STEC & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STEC
  • INKT
  • Stock Information
  • Founded
  • STEC 2006
  • INKT 2017
  • Country
  • STEC Hong Kong
  • INKT United States
  • Employees
  • STEC N/A
  • INKT N/A
  • Industry
  • STEC
  • INKT Medicinal Chemicals and Botanical Products
  • Sector
  • STEC
  • INKT Health Care
  • Exchange
  • STEC NYSE
  • INKT Nasdaq
  • Market Cap
  • STEC 29.7M
  • INKT 28.8M
  • IPO Year
  • STEC 2021
  • INKT 2021
  • Fundamental
  • Price
  • STEC $0.73
  • INKT $28.86
  • Analyst Decision
  • STEC
  • INKT Hold
  • Analyst Count
  • STEC 0
  • INKT 3
  • Target Price
  • STEC N/A
  • INKT $37.50
  • AVG Volume (30 Days)
  • STEC 12.9K
  • INKT 2.7M
  • Earning Date
  • STEC 07-22-2025
  • INKT 08-12-2025
  • Dividend Yield
  • STEC N/A
  • INKT N/A
  • EPS Growth
  • STEC N/A
  • INKT N/A
  • EPS
  • STEC N/A
  • INKT N/A
  • Revenue
  • STEC $10,672,000.00
  • INKT N/A
  • Revenue This Year
  • STEC $9,392.20
  • INKT N/A
  • Revenue Next Year
  • STEC N/A
  • INKT N/A
  • P/E Ratio
  • STEC N/A
  • INKT N/A
  • Revenue Growth
  • STEC N/A
  • INKT N/A
  • 52 Week Low
  • STEC $0.20
  • INKT $4.56
  • 52 Week High
  • STEC $3.25
  • INKT $76.00
  • Technical
  • Relative Strength Index (RSI)
  • STEC 32.63
  • INKT 60.80
  • Support Level
  • STEC $0.81
  • INKT $6.80
  • Resistance Level
  • STEC $0.88
  • INKT $76.00
  • Average True Range (ATR)
  • STEC 0.07
  • INKT 5.95
  • MACD
  • STEC -0.01
  • INKT 3.73
  • Stochastic Oscillator
  • STEC 35.80
  • INKT 35.31

About STEC SANTECH HOLDINGS LIMITED

Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Share on Social Networks: